Month: May 2022

Quincy, MA, May 11, 2022 (GLOBE NEWSWIRE) — Stran & Company, Inc. (“Stran” or the “Company”) (NASDAQ: STRN) (NASDAQ: STRNW), a leading outsourced marketing solutions provider that leverages its promotional products and loyalty incentive expertise, today announced it will host a conference call at 10:00 A.M. Eastern Time on Friday, May 13, 2022, to discuss the company’s financial results for the first quarter ended March 31, 2022, as well as the company’s corporate progress and other developments. The conference call will be available via telephone by dialing toll-free 888-506-0062 for U.S. callers or +1 973-528-0011 for international callers and using entry code: 832782. A webcast of the call may be accessed at https://www.webcaster4.com/Webcast/Page/2855/45543 or on the company’s Investors section...

OLINVYK refocused commercial strategy initiated mid-Q1 OLINVYK respiratory physiology study demonstrated statistically significant reduced impact on respiratory function compared to IV morphine, among elderly/overweight subjects Cognitive function study for OLINVYK versus IV morphine on track for topline results mid-year Continued progress of Phase I study for TRV045, novel S1P receptor modulator, for use in diabetic neuropathic pain (DNP); NIH preclinical studies in epilepsy ongoing Closed $40 million financing with R-Bridge Healthcare Fund; received first $15 million tranche in April 2022 Company to host conference call today, May 11th, 2022 at 8:00 a.m. ET CHESTERBROOK, Pa., May 11, 2022 (GLOBE NEWSWIRE) — Trevena, Inc. (Nasdaq:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines...

First Quarter Revenue Grew 271% Year-Over-Year to $26 Million, Exceeding Prior Guidance First Quarter Contractual Backlog Increased by $77 Million BILLERICA, Mass., May 11, 2022 (GLOBE NEWSWIRE) — Agrify™ Corporation (Nasdaq:AGFY) (“Agrify” or the “Company”), the most innovative provider of advanced cultivation and extraction solutions for the cannabis industry, today announced financial results for the first quarter ended March 31, 2022. “Increased customer adoption across our product lines not only fueled our Q1 growth but also helped strengthen the foundation for future high-margin recurring revenue streams, which we expect to begin to realize later this year,” said Raymond Chang, Chairman and Chief Executive Officer of Agrify. “We continue to make tremendous progress on the successful execution of our growth strategy...

18% increase in operating income, contractual agreements for 465 MW and 348 MW addition to project portfolio HighlightsIncreases in consolidated operating income and EBITDA(A)1in first quarter 2022Operating income of $91 million ($105 million)2 for Q1-2022, up 18% (16%) from $77 million ($91 million) in 2021 EBITDA(A) of $173 million ($183 million) for Q1-2022, up 14% (13%) from $151 million ($162 million) in 2021Partnership with Energy Infrastructure Partners (EIP) in FranceInvestment agreement signed and closed with EIP for the acquisition of a 30% stake in Boralex’s portfolio of operating assets and projects under development in France (recorded in Boralex’s financial statements as of April 29, 2022). Consideration received by Boralex totaling CAD $717 million4 (€532 million), of which $23 million4 (€17 million) related to...

Treatment Commences in Second Cohort of Phase 2 SHINE Study in Mild-to-Moderate Alzheimer’s Disease Data Presented at Scientific Conferences Further Validate the Potential of σ-2 Modulators PURCHASE, N.Y., May 11, 2022 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina (the “Company” or “Cognition”), today reported financial results for the first quarter ended March 31, 2022 and provided recent business updates. “Throughout the first quarter, we continued to drive the research and development of our lead programs with our objective to begin enrolling patients in our START trial with the ACTC and...

First quarter 2022 revenue increased 52% over prior year period BRANFORD, Conn., May 11, 2022 (GLOBE NEWSWIRE) — IsoPlexis Corporation (Nasdaq: ISO), the Superhuman Cell Company, today reported financial results for the quarter ended March 31, 2022. Recent HighlightsRevenue of $4.9 million for the first quarter 2022, representing a 52% increase over the corresponding period of 2021Sold 25 new instruments in the first quarter, bringing the installed base to 234 total instrumentsAnnounced the transition to an integrated commercial and operational structure to streamline and support sustainable growth as well as extend cash runway to the second half of 2024  Presented first-of-its-kind data on simultaneous single cell TCR profiling and highly-multiplexed functional proteomics at the American Association for Cancer Research...

Company to host conference call and webcast today, May 11, 2022, at 8:00 AM EDT FLORHAM PARK, N.J., May 11, 2022 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary Versamune® and Infectimune™ T-cell activating technologies, will discuss its financial results for the quarter ended March 31, 2022, and provide a business update on its conference call today. “2022 is shaping up to be an incredibly productive year for PDS Biotech,” commented Dr. Frank Bedu-Addo, President and Chief Executive Officer of the Company. “As we continue to make significant clinical progress on our lead oncology candidate, PDS0101, we’re looking ahead to presentations...

Immunocore Reports First Quarter 2022 Financial Results and Provides Business Update KIMMTRAK® (tebentafusp-tebn) approved in the United States and European Union for the treatment of unresectable or metastatic uveal melanoma Promotional launches and sales of KIMMTRAK ongoing in U.S., Germany, and France All patients in U.S. early access program successfully transitioned to commercial supply in Q1 Plan to report Phase 1 data from ImmTAC clinical candidates targeting PRAME (3Q 2022) and MAGE-A4 (4Q 2022) in multiple solid tumors this year Net KIMMTRAK and pre-product revenues of £10.5 million ($13.8 million) in Q1 2022 and net cash position of approximately $271 million as of March 31, 2022 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 11 May 2022) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the...

•  Planned Unblinded Interim Analysis of Phase 3 SHIELD I Trial of D-PLEX100 in Abdominal Soft Tissue Surgery Expected to Occur Imminently •  Recruitment Progressing as Planned with Approximately 900 Patients Enrolled into Phase 3 SHIELD I Trial of D-PLEX100 in Abdominal Soft Tissue Surgery •  Extended Cash Runway into the Second Quarter of 2023 with $15 million Non-Dilutive Secured Term Loan Facility •  Strengthened Executive Management Team •  Conference Call Scheduled for Today at 8:30 AM ET PETACH TIKVA, Israel, May 11, 2022 (GLOBE NEWSWIRE) — PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today provided a corporate update and reported financial results for the three months ended March 31, 2022. Recent Corporate Highlights:Unblinded interim analysis of...